Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Non-Hodgkin Lymphoma”

296 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 296 results

Large-scale testing (Phase 3)WithdrawnNCT00577161
What this trial is testing

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Who this might be right for
Non-Hodgkin's Lymphoma
CTI BioPharma
Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)WithdrawnNCT00003605
What this trial is testing

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Study completedNCT01263899
What this trial is testing

A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

Who this might be right for
Hodgkin LymphomaMantle Cell LymphomaIndolent Lymphoma
S*BIO 28
Testing effectiveness (Phase 2)Study completedNCT01206777
What this trial is testing

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Who this might be right for
Indolent or Intermediate Grade B-cell Malignancy
Ohio State University Comprehensive Cancer Center 52
Testing effectiveness (Phase 2)Study completedNCT00086034
What this trial is testing

Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

Who this might be right for
LymphomaNon-Hodgkin's Lymphoma
Pharmacyclics LLC. 35
Early research (Phase 1)Study completedNCT00052416
What this trial is testing

Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
Beth Israel Deaconess Medical Center
Large-scale testing (Phase 3)Study completedNCT01461928
What this trial is testing

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 692
Testing effectiveness (Phase 2)Looking for participantsNCT06530550
What this trial is testing

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Who this might be right for
Lymphoma, T-CellNK-LGL LeukemiaT-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China 51
Testing effectiveness (Phase 2)Study completedNCT00880581
What this trial is testing

Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Who this might be right for
Lymphoma, Non-HodgkinLymphomaLymphomas: Non-Hodgkin Follicular / Indolent B-Cell+1 more
Ronald Levy 30
Testing effectiveness (Phase 2)Study completedNCT03583424
What this trial is testing

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more
Ohio State University Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)Study completedNCT00240565
What this trial is testing

Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin
GlaxoSmithKline 93
Testing effectiveness (Phase 2)WithdrawnNCT07030699
What this trial is testing

Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center
Not applicableWithdrawnNCT02762448
What this trial is testing

Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas

Who this might be right for
Hepatitis c
Tainan Municipal Hospital
Testing effectiveness (Phase 2)Study completedNCT00720876
What this trial is testing

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
City of Hope Medical Center 30
Testing effectiveness (Phase 2)Ended earlyNCT02898259
What this trial is testing

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Who this might be right for
B Cell LymphomaLymphoma
Brian Hill 19
Not applicableStudy completedNCT00582270
What this trial is testing

Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma

Who this might be right for
Indolent Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 56
Not applicableUnknownNCT05803395
What this trial is testing

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Who this might be right for
Chronic Lymphocytic LeukemiaIndolent B-Cell Non-Hodgkin LymphomaCOVID-19
Gruppo Italiano Malattie EMatologiche dell'Adulto 954
Very early researchUnknownNCT04626739
What this trial is testing

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Who this might be right for
Refractory Indolent Adult Non-Hodgkin Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT00052572
What this trial is testing

Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 35
Load More Results